Can-Fite BioPharma (CANF) Price to Book (2016 - 2026)

Can-Fite BioPharma (CANF) has 11 years of Price to Book data on file, last reported at 0.5 in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 99.71% year-over-year to 0.5; the trailing twelve-month figure through Jun 2026 stood at 0.5 (down 99.71% YoY), and the FY2025 full-year result was 0.59, down 99.82% from the prior year.
• Price to Book was 0.5 for Q2 2026 at Can-Fite BioPharma, down from 0.59 in the prior quarter.
• In the past five years, Price to Book ranged from a high of 707.62 in Q2 2024 to a low of 0.5 in Q2 2026.
• A 5-year average of 256.15 and a median of 239.6 in 2023 frame the typical range for Price to Book.
• Across the five-year window, Price to Book jumped 288.46% in 2024 and sank 99.82% in 2025, its largest moves.
• Can-Fite BioPharma's Price to Book stood at 556.36 in 2022, then sank by 56.93% to 239.6 in 2023, then surged by 36.16% to 326.23 in 2024, then sank by 99.82% to 0.59 in 2025, then retreated by 14.48% to 0.5 in 2026.
• Per Business Quant data, the three most recent Price to Book figures were 0.5 in Q2 2026, 0.59 in Q4 2025, and 171.35 in Q2 2025.